BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang S, Sun J, Chen K, Ma P, Lei Q, Xing S, Cao Z, Sun S, Yu Z, Liu Y, Li N. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med 2021;19:140. [PMID: 34112147 DOI: 10.1186/s12916-021-02006-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Bomb K, Levalley PJ, Woodward IR, Cassel SE, Sutherland BP, Bhattacharjee A, Yun Z, Steen J, Kurdzo E, Mccoskey J, Burris D, Levine K, Carbrello C, Lenhoff AM, Fromen CA, Kloxin AM. Cell Therapy Biomanufacturing: Integrating Biomaterial and Flow‐Based Membrane Technologies for Production of Engineered T‐Cells. Adv Materials Technologies 2023. [DOI: 10.1002/admt.202201155] [Reference Citation Analysis]
2 Lu W, Xie B, Tan G, Dai W, Ren J, Pervaz S, Li K, Li F, Wang Y, Wang M. Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer. Front Endocrinol 2023;14. [DOI: 10.3389/fendo.2023.1088944] [Reference Citation Analysis]
3 Zhu X, You S, Du X, Song K, Lv T, Zhao H, Yao Q. LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer. BMC Med Genomics 2023;16:10. [PMID: 36653841 DOI: 10.1186/s12920-023-01435-9] [Reference Citation Analysis]
4 Chen Z, Sun X, Kang Y, Zhang J, Jia F, Liu X, Zhu H. A novel risk model based on the correlation between the expression of basement membrane genes and immune infiltration to predict the invasiveness of pituitary adenomas. Front Endocrinol (Lausanne) 2022;13:1079777. [PMID: 36686480 DOI: 10.3389/fendo.2022.1079777] [Reference Citation Analysis]
5 Hoh YK. The First Three Decades of Gene Therapy. The American Biology Teacher 2023;85:17-22. [DOI: 10.1525/abt.2023.85.1.17] [Reference Citation Analysis]
6 Fang KK, Lee JB, Zhang L. Adoptive Cell Therapy for T-Cell Malignancies. Cancers (Basel) 2022;15. [PMID: 36612092 DOI: 10.3390/cancers15010094] [Reference Citation Analysis]
7 Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A. Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. JACC CardioOncol 2022;4:616-23. [PMID: 36636447 DOI: 10.1016/j.jaccao.2022.07.014] [Reference Citation Analysis]
8 Jimeno A, Baranda J, Iams WT, Park JC, Mita M, Gordon MS, Taylor M, Dhani N, Leal AD, Neupane P, Eng C, Yeku O, Mita A, Moser JC, Butler M, Loughhead SM, Jennings J, Miselis NR, Ji R, Nair N, Kornacker M, Zwirtes RF, Bernstein H, Sharei A. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ- PBMC-HPV) in HLA-A*02+ patients with HPV16+ Solid Tumors.. [DOI: 10.21203/rs.3.rs-2355585/v1] [Reference Citation Analysis]
9 Yi X, Hu W. Advances in adoptive cellular therapy for colorectal cancer: a narrative review. Ann Transl Med 2022;10:1404. [PMID: 36660664 DOI: 10.21037/atm-22-6196] [Reference Citation Analysis]
10 Martin R, Lei R, Zeng Y, Zhu J, Chang H, Ye H, Cui Z. Membrane Applications in Autologous Cell Therapy. Membranes (Basel) 2022;12. [PMID: 36557091 DOI: 10.3390/membranes12121182] [Reference Citation Analysis]
11 Teppert K, Wang X, Anders K, Evaristo C, Lock D, Künkele A. Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR". Int J Mol Sci 2022;23. [PMID: 36498890 DOI: 10.3390/ijms232314563] [Reference Citation Analysis]
12 Huang Z, Wang G, Wu Y, Yang T, Shao L, Yang B, Li P, Li J. N6-methyladenosine-related lncRNAs in combination with computational histopathology and radiomics predict the prognosis of bladder cancer. Transl Oncol 2022;27:101581. [PMID: 36327698 DOI: 10.1016/j.tranon.2022.101581] [Reference Citation Analysis]
13 Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, Falak R. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1018962] [Reference Citation Analysis]
14 Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F, Zhang L, Yi Z, Long L, Yan L, Wang Z, Zhang N, Luo P, Zhang J, Liu Z, Ye W, Liu Z, Cheng Q. Tumor buster - where will the CAR-T cell therapy 'missile' go? Mol Cancer 2022;21:201. [PMID: 36261831 DOI: 10.1186/s12943-022-01669-8] [Reference Citation Analysis]
15 Huang H, Long Z, Xie Y, Qin P, Kuang L, Li X, Zhao Y, Zhang X, Yang L, Ma W, Xiao X, Liu Y, Sun X, Zhang M, Wang F, Hu D, Hu F, Han H. Molecular Subtypes Based on Cuproptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Colorectal Cancer. Journal of Oncology 2022;2022:1-19. [DOI: 10.1155/2022/5034092] [Reference Citation Analysis]
16 Sheng S, Lu C, Guo J, Liu M, Wu Y, Cigerci İH. Immune Effect of T Lymphocytes Infiltrated by Tumors on Non-Small-Cell Lung Cancer. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/4662874] [Reference Citation Analysis]
17 Mishra AK, Ali A, Dutta S, Banday S, Malonia SK. Emerging Trends in Immunotherapy for Cancer. Diseases 2022;10:60. [DOI: 10.3390/diseases10030060] [Reference Citation Analysis]
18 Feng H, Qiu L, Shi Z, Sheng Y, Zhao P, Zhou D, Li F, Yu H, You Y, Wang H, Li M, Zhu S, Du Y, Cui J, Sun J, Liu Y, Jiang H, Wu X. Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy. Cancer Med 2022. [PMID: 36028997 DOI: 10.1002/cam4.5095] [Reference Citation Analysis]
19 Yunger S, Geiger B, Friedman N, Besser MJ, Adutler-lieber S. Modulating the proliferative and cytotoxic properties of human TIL by a synthetic immune niche of immobilized CCL21 and ICAM1.. [DOI: 10.1101/2022.07.07.499105] [Reference Citation Analysis]
20 Alkhouli MA, Bazargan S, Pilon-Thomas S, Poch M, Chahoud J. Current State of Cell Therapies for Genitourinary Malignancies. Cancer J 2022;28:294-300. [PMID: 35880939 DOI: 10.1097/PPO.0000000000000604] [Reference Citation Analysis]
21 Mullinax JE, Egger ME, McCarter M, Monk BJ, Toloza EM, Brousseau S, Jagasia M, Sarnaik A. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Cancer J 2022;28:285-93. [PMID: 35880938 DOI: 10.1097/PPO.0000000000000608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol 2022;13:835762. [PMID: 35309357 DOI: 10.3389/fimmu.2022.835762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Nowroozi A, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms. Expert Opin Biol Ther 2022. [PMID: 35477305 DOI: 10.1080/14712598.2022.2072206] [Reference Citation Analysis]
24 Li J, Chen D, Shen M. Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses. Front Med 2022;9:869010. [DOI: 10.3389/fmed.2022.869010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Lechpammer M, Rao R, Shah S, Mirheydari M, Bhattacharya D, Koehler A, Toukam DK, Haworth KJ, Pomeranz Krummel D, Sengupta S. Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers. Cancers (Basel) 2022;14:1627. [PMID: 35406398 DOI: 10.3390/cancers14071627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Choi S, Park S, Kim H, Kang SY, Ahn S, Kim K. Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. Biomedicines 2022;10:543. [DOI: 10.3390/biomedicines10030543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zhang X, Liu K, Zhang K, Li X, Sun Z, Wei B. SAMS-Net: Fusion of attention mechanism and multi-scale features network for tumor infiltrating lymphocytes segmentation. MBE 2022;20:2964-2979. [DOI: 10.3934/mbe.2023140] [Reference Citation Analysis]
28 Serrano-López J, Martín-Antonio B. Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly. Cells 2021;10:2562. [PMID: 34685542 DOI: 10.3390/cells10102562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Louis W, Guorong L, Anne-emmanuelle B, Claude L. Flow cytometry potential applications in characterizing solid tumors main phenotype, heterogeneity and circulating cells. Arch Pathol Clin Res 2021;5:010-015. [DOI: 10.29328/journal.apcr.1001022] [Reference Citation Analysis]